Evidence map›Paper›PMID 40777348›Full record

ArticlebioRxiv : the preprint server for biology2025

Small molecule intervention of actin-binding protein profilin1 reduces tumor angiogenesis in renal cell carcinoma.

David Gau, Pooja Chawla, Kexin Xu, Niharika Welling, Jacob Antonello, Caroline Consoli, Monica Wei, Sara Zdancewicz, Michael DaSilva, Chris Varghese and 10 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

David GauDepartment of Pathology, University of Pittsburgh.
Pooja ChawlaDepartment of Bioengineering, University of Pittsburgh.
Kexin XuDepartment of Chemistry, University of Pennsylvania.
Niharika WellingDepartment of Computational and Systems Biology.
Jacob AntonelloDepartment of Bioengineering, University of Pittsburgh.
Caroline ConsoliDepartment of Chemistry, University of Pennsylvania.
Monica WeiDepartment of Chemistry, University of Pennsylvania.
Sara ZdancewiczDepartment of Biology, University of Pittsburgh.
Michael DaSilvaDepartment of Biology, University of Pittsburgh.
Chris VargheseDepartment of Bioengineering, University of Pittsburgh.
Paul FrancoeurDepartment of Computational and Systems Biology.
Haibin ShiDepartment of Microbiology and Molecular Genetics, University of Pittsburgh.
Xucai ChenDepartment of Medicine, University of Pittsburgh.
Anurag ParanjapeDepartment of Medicine, University of Pittsburgh.
Flordeliza VillanuevaDepartment of Medicine, University of Pittsburgh.
Thomas E SmithgallDepartment of Microbiology and Molecular Genetics, University of Pittsburgh.
Andrew VanDemarkDepartment of Biology, University of Pittsburgh.ORCID 0000-0003-3424-4831
David R KoesDepartment of Computational and Systems Biology.
Donna M HurynDepartment of Chemistry, University of Pennsylvania.
Partha RoyDepartment of Pathology, University of Pittsburgh.

Funding

Training Program in Imaging Sciences in Translational Cardiovascular ResearchT32HL129964 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Flordeliza S Villanueva · 2016 to 2026
$4.7M
Profilin biology in breast cancerR01CA248873 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ROY, PARTHA · 2021 to 2025
$1.8M
Transcriptional Regulation of Dormancy and Emergence in Breast CancerR01CA271095 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PARTHA ROY · 2023 to 2026
$1.5M
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapyK08CA267189 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sangeetha Meda Reddy · 2022 to 2026
$1.2M
Discovery of Cell-based Chemical Probes Targeting Aberrant Angiogenesis in the EyeR21EY032632 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HURYN, DONNA M, KOES, DAVID RYAN · 2022 to 2023
$426k
NCI NIH HHS K08 CA267189NCI NIH HHS R01 CA248873NCI NIH HHS R01 CA271095NEI NIH HHS R21 EY032632NHLBI NIH HHS T32 HL129964
6 · The paper itself

Abstract

Angiogenesis plays a key role in the development and progression of renal cell carcinoma (RCC). Actin-binding protein profilin-1 (Pfn1) is overexpressed in clear cell RCC predominantly in tumor-associated vascular endothelial cells (ECs). We previously demonstrated that that EC-selective (over)expression of Pfn1 accelerates RCC progression, and conversely, genetic loss of EC-Pfn1 dramatically inhibits tumor angiogenesis impeding tumor initiation and/or progression in RCC, suggesting that Pfn1 could be an actionable therapeutic target in RCC. In this study, we demonstrate that 4,4'-((4-bromophenyl)methylene)bis(3,5-dimethyl-1

Indexed as

actinangiogenesismicrobubblesProfilinrenal cell carcinoma

Identifiers

PMID40777348
PMCPMC12330497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.